UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
Kinase Fusion Gene:ROCK2_LPIN1 |
Kinase Fusion Protein Summary |
Kinase Fusion gene summary |
Kinase Fusion partner gene information | Kinase Fusion gene name: ROCK2_LPIN1 | KinaseFusionDB ID: KFG5453 | FusionGDB2.0 ID: KFG5453 | Hgene | Tgene | Gene symbol | ROCK2 | LPIN1 | Gene ID | 9475 | 23175 | |
Gene name | Rho associated coiled-coil containing protein kinase 2 | lipin 1 | ||||||||||
Synonyms | ROCK-II | PAP1 | ||||||||||
Cytomap | 2p25.1 | 2p25.1 | ||||||||||
Type of gene | protein-coding | protein-coding | ||||||||||
Description | rho-associated protein kinase 2p164 ROCK-2rho-associated, coiled-coil-containing protein kinase II | phosphatidate phosphatase LPIN1 | ||||||||||
Modification date | 20240403 | 20240305 | ||||||||||
UniProtAcc | O75116 | Q14693 | ||||||||||
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000315872, ENST00000401753, ENST00000462366, | ENST00000256720, ENST00000396097, ENST00000396098, ENST00000404113, ENST00000464517, ENST00000396099, ENST00000425416, ENST00000449576, | |||||||||
Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: ROCK2 [Title/Abstract] AND LPIN1 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | ROCK2(11332274)-LPIN1(11905659), # samples:1 |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | ROCK2 | GO:0006468 | protein phosphorylation | 18559669 |
Tgene | LPIN1 | GO:0019432 | triglyceride biosynthetic process | 29765047 |
Kinase Fusion gene breakpoints across ROCK2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Kinase Fusion gene breakpoints across LPIN1 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
Kinase Fusion gene information. |
Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
ChimerDB4 | TCGA-CR-7392-01A | ROCK2 | chr2 | 11332274 | LPIN1 | chr2 | 11905659 |
Top |
Kinase Fusion ORF Analysis |
Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:11332274/:11905659) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
ROCK2 | LPIN1 |
FUNCTION: Protein kinase which is a key regulator of actin cytoskeleton and cell polarity. Involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of ADD1, BRCA2, CNN1, EZR, DPYSL2, EP300, MSN, MYL9/MLC2, NPM1, RDX, PPP1R12A and VIM. Phosphorylates SORL1 and IRF4. Acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation. Positively regulates the activation of p42/MAPK1-p44/MAPK3 and of p90RSK/RPS6KA1 during myogenic differentiation. Plays an important role in the timely initiation of centrosome duplication. Inhibits keratinocyte terminal differentiation. May regulate closure of the eyelids and ventral body wall through organization of actomyosin bundles. Plays a critical role in the regulation of spine and synaptic properties in the hippocampus. Plays an important role in generating the circadian rhythm of the aortic myofilament Ca(2+) sensitivity and vascular contractility by modulating the myosin light chain phosphorylation. {ECO:0000269|PubMed:10579722, ECO:0000269|PubMed:15699075, ECO:0000269|PubMed:16574662, ECO:0000269|PubMed:17015463, ECO:0000269|PubMed:19131646, ECO:0000269|PubMed:19997641, ECO:0000269|PubMed:21084279, ECO:0000269|PubMed:21147781}. | FUNCTION: Acts as a magnesium-dependent phosphatidate phosphatase enzyme which catalyzes the conversion of phosphatidic acid to diacylglycerol during triglyceride, phosphatidylcholine and phosphatidylethanolamine biosynthesis and therefore controls the metabolism of fatty acids at different levels (PubMed:20231281, PubMed:29765047). Is involved in adipocyte differentiation (By similarity). Acts also as nuclear transcriptional coactivator for PPARGC1A/PPARA regulatory pathway to modulate lipid metabolism gene expression (By similarity). Recruited at the mitochondrion outer membrane and is involved in mitochondrial fission by converting phosphatidic acid to diacylglycerol (By similarity). {ECO:0000250|UniProtKB:Q91ZP3, ECO:0000269|PubMed:20231281, ECO:0000269|PubMed:29765047}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
- Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of ROCK2_LPIN1 |
Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
ROCK2 | O75116 | human | SLC9A1 | P19634 | T653 | LRsYNRHtLVADPyE | NEXCaM_BD |
ROCK2 | O75116 | human | BACE1 | P56817 | S498 | DDFADDIsLLk____ | |
ROCK2 | O75116 | human | MYL2 | P10916 | S15 | KRAGGANsNVFsMFE | |
ROCK2 | O75116 | human | PPP1R14A | Q96A00 | T38 | QkRHARVtVkYDRRE | PP1_inhibitor |
ROCK2 | O75116 | human | ROCK2 | O75116 | S1374 | MkIQQNQsIRRPsRQ | |
ROCK2 | O75116 | human | SH3GL2 | Q99962 | T14 | KKQFHKAtQKVSEKV | BAR |
ROCK2 | O75116 | human | ROCK2 | O75116 | S1366 | ARssPRtsMkIQQNQ | |
ROCK2 | O75116 | human | LIMK2 | P53671 | T505 | NDRKKRYtVVGNPYW | PK_Tyr_Ser-Thr |
ROCK2 | O75116 | human | VIM | P08670 | S72 | ssAVrLrssVPGVRL | Filament_head |
ROCK2 | O75116 | human | EEF1A1 | P68104 | T432 | AVRDMrQtVAVGVIk | GTP_EFTU_D3 |
ROCK2 | O75116 | human | PPP1R12A | O14974 | T696 | ARQsRRstQGVtLtD | |
ROCK2 | O75116 | human | ROCK2 | O75116 | S1379 | NQsIRRPsRQLAPNK | |
ROCK2 | O75116 | human | NCF1 | P14598 | S345 | QARPGPQsPGsPLEE | |
ROCK2 | O75116 | human | SORL1 | Q92673 | S2206 | APMITGFsDDVPMVI | |
ROCK2 | O75116 | human | DPYSL2 | Q16555 | T555 | DNIPRRttQRIVAPP | |
ROCK2 | O75116 | human | NFATC1 | O95644 | S241 | PRHsPSTsPRAsVTE | |
ROCK2 | O75116 | human | DAB2 | P98082 | S723 | KPAPRQVsLPVTkst | |
ROCK2 | O75116 | human | APP | P05067-4 | T654 | MLKKKQYtsIHHGVV | APP_amyloid |
ROCK2 | O75116 | human | CNN3 | Q15417 | S293 | QGtGTNGsEIsDSDy | |
ROCK2 | O75116 | human | PPP1R14B | Q96C90 | T57 | VRRQGKVtVkYDRKE | PP1_inhibitor |
Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
Enriched GO biological processes of the phosphorylation target genes of the kinase |
Kinase | GOID | GO term | P.adjust |
ROCK2 | ID | Description | 0.00e+00 |
ROCK2 | GO:1901653 | cellular response to peptide | 8.73e-04 |
ROCK2 | GO:0034205 | amyloid-beta formation | 6.19e-03 |
ROCK2 | GO:0050435 | amyloid-beta metabolic process | 6.19e-03 |
ROCK2 | GO:0042987 | amyloid precursor protein catabolic process | 6.19e-03 |
ROCK2 | GO:1905245 | regulation of aspartic-type peptidase activity | 6.19e-03 |
ROCK2 | GO:0031032 | actomyosin structure organization | 6.19e-03 |
ROCK2 | GO:0071394 | cellular response to testosterone stimulus | 6.19e-03 |
ROCK2 | GO:1902946 | protein localization to early endosome | 6.19e-03 |
ROCK2 | GO:1905668 | positive regulation of protein localization to endosome | 6.19e-03 |
ROCK2 | GO:1905666 | regulation of protein localization to endosome | 6.58e-03 |
ROCK2 | GO:0016049 | cell growth | 7.19e-03 |
ROCK2 | GO:1903651 | positive regulation of cytoplasmic transport | 7.38e-03 |
ROCK2 | GO:0042982 | amyloid precursor protein metabolic process | 7.49e-03 |
ROCK2 | GO:0007176 | regulation of epidermal growth factor-activated receptor activity | 1.03e-02 |
ROCK2 | GO:0043500 | muscle adaptation | 1.20e-02 |
ROCK2 | GO:0002026 | regulation of the force of heart contraction | 1.70e-02 |
ROCK2 | GO:0036010 | protein localization to endosome | 1.72e-02 |
ROCK2 | GO:0043393 | regulation of protein binding | 1.72e-02 |
ROCK2 | GO:1903649 | regulation of cytoplasmic transport | 2.18e-02 |
ROCK2 | GO:0010613 | positive regulation of cardiac muscle hypertrophy | 2.48e-02 |
ROCK2 | GO:0014742 | positive regulation of muscle hypertrophy | 2.50e-02 |
ROCK2 | GO:0003180 | aortic valve morphogenesis | 2.59e-02 |
ROCK2 | GO:0071364 | cellular response to epidermal growth factor stimulus | 2.59e-02 |
ROCK2 | GO:1990000 | amyloid fibril formation | 2.59e-02 |
ROCK2 | GO:0031345 | negative regulation of cell projection organization | 2.59e-02 |
ROCK2 | GO:0003176 | aortic valve development | 2.59e-02 |
ROCK2 | GO:0014002 | astrocyte development | 2.59e-02 |
ROCK2 | GO:1904646 | cellular response to amyloid-beta | 2.59e-02 |
ROCK2 | GO:0003012 | muscle system process | 2.59e-02 |
ROCK2 | GO:0033173 | calcineurin-NFAT signaling cascade | 2.59e-02 |
ROCK2 | GO:0033574 | response to testosterone | 2.59e-02 |
ROCK2 | GO:0070849 | response to epidermal growth factor | 2.59e-02 |
ROCK2 | GO:0043666 | regulation of phosphoprotein phosphatase activity | 2.59e-02 |
ROCK2 | GO:1905314 | semi-lunar valve development | 2.59e-02 |
ROCK2 | GO:0097720 | calcineurin-mediated signaling | 2.59e-02 |
ROCK2 | GO:1902003 | regulation of amyloid-beta formation | 2.59e-02 |
ROCK2 | GO:0098927 | vesicle-mediated transport between endosomal compartments | 2.60e-02 |
ROCK2 | GO:1901888 | regulation of cell junction assembly | 2.60e-02 |
ROCK2 | GO:0044788 | modulation by host of viral process | 2.60e-02 |
ROCK2 | GO:0010810 | regulation of cell-substrate adhesion | 2.77e-02 |
ROCK2 | GO:1904645 | response to amyloid-beta | 2.77e-02 |
ROCK2 | GO:1902991 | regulation of amyloid precursor protein catabolic process | 2.91e-02 |
ROCK2 | GO:0061097 | regulation of protein tyrosine kinase activity | 2.95e-02 |
ROCK2 | GO:0061462 | protein localization to lysosome | 3.27e-02 |
ROCK2 | GO:0003179 | heart valve morphogenesis | 3.27e-02 |
ROCK2 | GO:0010921 | regulation of phosphatase activity | 3.27e-02 |
ROCK2 | GO:0090257 | regulation of muscle system process | 3.27e-02 |
ROCK2 | GO:0051893 | regulation of focal adhesion assembly | 3.27e-02 |
ROCK2 | GO:0090109 | regulation of cell-substrate junction assembly | 3.27e-02 |
Top |
Related Drugs to ROCK2_LPIN1 |
Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Distribution of the number of studies mentioning ROCK2-LPIN1 and kinase inhibitors the PubMed Abstract (04-01-2024) |
Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to ROCK2_LPIN1 |
Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
MeSH ID | MeSH term |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
Clinical Trials from clinicaltrials.gov (06-17-2024) |
Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |